Scrip
Roche and Biogen Idec's ocrelizumab positive in first Phase III trial for RA
16 December 2009
Katie McQue
Please Login to read the full article.
16 December 2009
Katie McQue
katie.mcque@informa.com
Roche and Biogen Idec's humanised anti-CD20 monoclonal antibody ocrelizumab has met the primary endpoint of its first Phase III study in rheumatoid arthritis (RA), top-line data of the STAGE trial show.
The announcement came shortly after it was revealed that ocrelizumab achieved positive...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
